Key Highlights

  • Shares are trading down about 3.30% today in a broader weak market.
  • Merck discontinued its entire BELLWAVE program for nemtabrutinib, a BTK inhibitor.
  • The decision followed a data monitoring committee review of Phase 3 results.
  • The board separately named a new independent lead director, effective January 1.
  • Outgoing lead director Thomas Glocer will retire from the board in May 2027.

Merck (NYSE:MRK) shares are trading lower today after the company announced it is discontinuing the entire clinical development program evaluating nemtabrutinib, an investigational oral Bruton's tyrosine kinase inhibitor being studied for blood cancers. Merck is a global research-intensive biopharmaceutical company operating through Pharmaceutical and Animal Health segments, with its oncology portfolio anchored by its flagship immunotherapy.

Data Monitoring Review Prompts Program-Wide Discontinuation

The decision followed a review by an external data monitoring committee of the Phase 3 BELLWAVE-011 trial, which suggested the treatment's benefits may not outweigh its risks. After confirming the finding through a review of the full dataset, Merck decided to discontinue the broader BELLWAVE program, including two additional Phase 3 studies, BELLWAVE-008 and BELLWAVE-010.

Company Says It Remains Focused on Hematology Pipeline

A senior Merck oncology research executive said the company remains grateful to patients, caregivers, and investigators involved in the studies and will continue pursuing other approaches to help patients with blood cancers. Data analyses from the discontinued trials are ongoing, with results to be shared with the scientific community.

Board Separately Announces Lead Director Transition

In a separate announcement, Merck said Thomas Glocer intends to retire from the board at the company's annual Shareholder meeting in May 2027. Douglas Baker, who has served on the board since 2022 and previously led Ecolab as chairman and CEO, has been appointed independent lead director effective January 1, 2027.

What Comes Next for Merck's Pipeline

With the BELLWAVE program now discontinued, investors are likely to watch for updates on Merck's remaining hematology and broader oncology pipeline programs as the company looks to offset the setback.